Thromboembolism and pancreatic cancer.

Venous thromboembolism (VTE) is a frequent event in the clinical course of patients with exocrine pancreatic cancer; studies have been designed to evaluate the role of prophylactic anticoagulation in this ominous disease. Searching for the molecular basis of thrombosis in cancer, Bozkurt et al. present in the Abstract #e22049 the result of their investigation on the frequency of inherited and carcinogenesis-acquired proteins in oncologic patients with and without venous thromboembolism. From the bedside, Muñoz Martin et al. present in the Abstract #e15187 their work on the incidence of venous thromboembolism in patients with exocrine pancreatic cancer and the role of the established Khorana score in predicting symptomatic and incidental venous thromboembolism. At last, Cella et al. in the Abstract #e20625 expand the predictor landscape from the Khorana score to other risk factors for venous thromboembolism, refining the selection of oncologic patients who can benefit from prophylactic anticoagulation.

[1]  K. Aydın,et al.  The impact of prothrombotic mutations, PSGL-1 VNTR polymorphism, tissue factor, and soluble P-selectin on venous thromboembolism in cancer patients with adenocarcinoma. , 2014 .

[2]  P. Jiménez-Fonseca,et al.  Incidence of incidental and symptomatic venous thromboembolism (VTE) and Khorana’s score in ambulatory pancreatic cancer patients receiving chemotherapy. , 2014 .

[3]  B. Dörken,et al.  Intensified chemotherapy and simultaneous treatment with heparin in outpatients with pancreatic cancer – the CONKO 004 pilot trial , 2014, BMC Cancer.

[4]  I. Pabinger,et al.  Microparticle-associated tissue factor activity in patients with metastatic pancreatic cancer and its effect on fibrin clot formation. , 2014, Translational research : the journal of laboratory and clinical medicine.

[5]  G. Lyman,et al.  Venous thromboembolism risk in patients with cancer receiving chemotherapy: a real-world analysis. , 2013, The oncologist.

[6]  I. Pabinger,et al.  Biomarkers for prediction of venous thromboembolism in cancer. , 2013, Blood.

[7]  N. Mackman,et al.  Tumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients. , 2013, Blood.

[8]  M. Saif,et al.  Thromboembolism and anticoagulation in pancreatic cancer. , 2013, JOP : Journal of the pancreas.

[9]  A. Khorana,et al.  International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer , 2013, Journal of thrombosis and haemostasis : JTH.

[10]  A. Khorana,et al.  Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy. , 2010, Thrombosis research.

[11]  M. Singer,et al.  Prospective study on warfarin and regional chemotherapy in patients with pancreatic carcinoma. , 2008, Journal of gastrointestinal and liver diseases : JGLD.

[12]  Gary H Lyman,et al.  Development and validation of a predictive model for chemotherapy-associated thrombosis. , 2008, Blood.

[13]  B. Yalcin,et al.  Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer , 2007, Journal of surgical oncology.

[14]  A. Khorana,et al.  Risk factors for chemotherapy‐associated venous thromboembolism in a prospective observational study , 2005, Cancer.

[15]  M. Cushman,et al.  Risk factors for venous thrombosis in medical inpatients: validation of a thrombosis risk score , 2004, Journal of thrombosis and haemostasis : JTH.

[16]  Bohn Stafleu van Loghum,et al.  Online … , 2002, LOG IN.

[17]  M. Menon,et al.  Venous thromboembolism after major cancer surgery: temporal trends and patterns of care. , 2014, JAMA surgery.

[18]  I. Pabinger,et al.  Risk of venous thromboembolism and primary prophylaxis in cancer , 2012, Hämostaseologie.